Wide variation seen in gluten-free food prescribing

Wide variation seen in gluten-free food prescribing

April 20 2018 Wide variation in gluten-free food (GFF) prescribing does not appear to be driven...

‘Caution in use’ alert issued for Inhixa solution for injection

‘Caution in use’ alert issued for Inhixa solution for injection

April 20 2018 A Class 4 medicines defect alert has been issued relating to Inhixa (enoxaparin...

Views sought on improving health services for people with sensory loss

Views sought on improving health services for people with sensory loss

April 20 2018 Primary care professionals are being asked for views on how to help improve...

Minister: GPs are not precluded from prescribing OTC medicines, but should follow guidance

Minister: GPs are not precluded from prescribing OTC medicines, but should follow guidance

April 20 2018 Doctors have not been prevented from prescribing over-the counter medicines, but...

Epipen manufacturing delays causing stock shortage

Epipen manufacturing delays causing stock shortage

April 17 2018 A manufacturing delay is causing problems around availability of Epipen (Senior)...

  • Wide variation seen in gluten-free food prescribing

    Wide variation seen in gluten-free food prescribing

    Friday, 20 April 2018 16:48
  • ‘Caution in use’ alert issued for Inhixa solution for injection

    ‘Caution in use’ alert issued for Inhixa solution for injection

    Friday, 20 April 2018 16:43
  • Views sought on improving health services for people with sensory loss

    Views sought on improving health services for people with sensory loss

    Friday, 20 April 2018 16:39
  • Minister: GPs are not precluded from prescribing OTC medicines, but should follow guidance

    Minister: GPs are not precluded from prescribing OTC medicines, but should follow guidance

    Friday, 20 April 2018 16:31
  • Epipen manufacturing delays causing stock shortage

    Epipen manufacturing delays causing stock shortage

    Tuesday, 17 April 2018 08:53

adhdDecember 2 2015

Researchers have urged doctors to be cautious if considering prescribing methylphenidate for children or adolescents with attention deficit hyperactivity disorder (ADHD).

A Cochrane review has concluded that the drug may improve teacher-reported ADHD symptoms, teacher-reported general behaviour, and parent-reported quality of life among children and adolescents diagnosed with ADHD. “However, the low quality of the underpinning evidence means that we cannot be certain of the magnitude of the effects.”

The researchers assessed 38 parallel-group trials and 147 cross-over trials, representing over 12,200 patients, and found methylphenidate led to “modest” improvements in ADHD symptoms as a primary outcome. They also found there were improvements in general behaviour and quality of life. However, in all outcomes, the quality of the evidence was judged to be “very low”.

Data for serious adverse events was only reported in nine out of the 185 trials, meaning that while methylphenidate does not appear to be associated with an increased risk of serious adverse events, the quality of the evidence was again very low.

“It was apparent from assessing the included trials that it would have been possible for people involved in the trials to have been aware of which treatment the children were taking,” says Cochrane. “In addition, the reporting of results was not complete in many of the trials, and for some analyses there was variation among trial results.

“Based upon this information, the researchers urge clinicians to be cautious in prescribing methylphenidate, and to weigh up the benefits and risks more carefully.”

Professor Ole Jakob Storebø, a clinical psychologist from the Psychiatric Research Unit in Region Zealand, Denmark, led the team of 18 researchers carrying out the meta-analysis. “This review highlights the need for long-term, large, better-quality randomized trials so that we can determine the average effect of this drug more reliably,” he said.

Co-author Camilla Groth MD added: “This review shows very limited quality evidence for the effects of methylphenidate on children and adolescents with ADHD. Some might benefit, but we still don’t know which patients will do so. Clinicians prescribing methylphenidate must take account of the poor quality of the evidence, monitor treatment carefully, and weigh up the benefits and adverse effects.”

Links:

Cochrane announcement

Cochrane review summary

Ole Jakob Storebø et al. ‘Methylphenidate for children and adolescents with attention deficit hyperactivity disorder (ADHD)’. Cochrane Library. Published online November 25 2015.

Professional News

April 20 2018 Wide variation in gluten-free food (GFF) prescribing does not appear to be driven by obvious medical factors, a study has suggested. 
April 20 2018 Wide variation in gluten-free food (GFF) prescribing does not appear to be driven by obvious medical factors, a study has suggested.  GFF prescribing is less likely to occur in areas...